Is Pfizer Stock a Buy? [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
But for investors, it could still be a great pickup once a few of the loftier expectations about its future are safely in check. Let's start by hearing from the bears about why the stock isn't a buy, and then look at the other side's argument. The last couple of years have been tough Under normal conditions, one might expect that a big pharma business, with a large portfolio of essential drugs and a recent run of best-selling medicines like the Comirnaty coronavirus vaccine, would be booming. In such a scenario, the investing thesis would be obvious -- buy the stock, because the company has a knack for making it go up consistently over time by successfully developing the right drugs for the right markets. But that isn't the situation that Pfizer is in today. Far from being a reigning champion, it now looks closer to being a washed-up former contender. In case you haven't been keeping up with the stock price, the total return of its shares is down by 19% over the last three year
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Biodexa gains license for polyposis asset as stock more than doubles [Yahoo! Finance]Yahoo! Finance
- Carboprost Tromethamine Market to Gain 2.96 Billion, by 2033 with 4% CAGR: States The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- A Better Concept For mRNA Vaccines: Self-Amplification [Forbes]Forbes
- Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual MeetingBusiness Wire
PFE
Earnings
- 1/30/24 - Beat
PFE
Sec Filings
- 4/29/24 - Form 8-K
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- PFE's page on the SEC website